A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 25, Issue 5, 2005, Pages 441-447

  Fava, Maurizio ^a   Alpert, Jonathan ^a   Nierenberg, Andrew A ^a   Mischoulon, David ^a   Otto, Michael W ^a   Zajecka, John ^b   Murck, Harald ^c   Rosenbaum, Jerrold F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Lichtwer Pharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; PLACEBO;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HUMAN; INFLUENZA; MAJOR DEPRESSION; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; FLUOXETINE; HUMANS; HYPERICUM; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 25444520063     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000178416.60426.29     Document Type: Article

References (15)

1. Nierenberg AA, Mischoulon D, DeCecco L. St. John's wort: a critique of antidepressant efficacy and possible mechanism of action. In: Mischoulon D, Rosenbaum JF, eds. Natural Medications for Psychiatric Disorders. Philadelphia, PA: Lippincott Williams and Wilkins; 2002:3-12.
2. Linde K, Ramirez G, Mulrow CD, et al. St John's wort for depression- an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313(7052):253-258.
3. Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA. 2001;285(15):1978-1986.
4. Hamilton M. A rating scale for depressions. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
5. Otto MW, Nierenberg AA. Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom. September-October 2002;71(5):241-243.
6. Hooper M, Amsterdam JD. Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants. Poster presented at: NCDEU 39th Annual Meeting; June 11-14, 1998; Boca Raton, Fla.
7. Hypericum Depression Study Group. Effect of Hypericum perforatum (St. John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807-1814.
8. Kupfer DJ, Frank E. Placebo in clinical trials for depression: complexity and necessity. JAMA. 2002;287(14):1853-1854.
9. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-Axis I Disorders-Patient Edition (SCID-I/P, Version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute; 1995.
10. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rev Ed DHEW Publication No. (ADM) 7-338. National Institute of Mental Health: Rockville, MD; 1976.
11. Beck AT, Ward CE, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
12. Lecubrier Y, Clerc G, Didi R, et al. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 2002;159:1361-1366.
13. Fava M, Rosenbaum JF, McGrath PJ, et al. A double-blind, controlled study of lithium and tricyclic augmentation of fluoxetine in treatment resistant depression. Am J Psychiatry. 1994;151:1372-1374.
14. Fava M, Alpert J, Nierenberg AA, et al. Double-blind study of high-dose fluoxetine vs. lithium or desipramine augmentation of fluoxetine in partial and non-responders to fluoxetine. J Clin Psychopharmacol. August 2002;22(4):379-387.
15. Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. April 2002;22 (2):137-147.